osteoporosis
OSTEOPOROSIS
Osteoporosis is the progressive, systemic skeletal disease characterized by decreased bone mass and micro-architectural deterioration of bone tissue leading to increased bone fragility and susceptibility to fractures.
The more risk factors (eg history, of fracture, advanced age, comorbidities, impaired vision) that are present, the greater the risk of fracture.

Definition

  • Progressive, systemic skeletal disease characterized by decreased bone mass and micro-architectural deterioration of bone tissue leading to increased bone fragility and susceptibility to fractures
    • Bone strength, reflecting both density and quality of the bone, is compromised thus increasing fracture risk
    • Fractures commonly occur in the hip, spine and wrist with the hip fractures having a high morbidity
  • Common presentations: Back pain, low-trauma fracture, height loss, increasing dorsal kyphosis
  • Though osteoporosis in Asia is very much underdiagnosed and undertreated, it is projected that by 2050, >50% of osteoporotic hip fractures will happen in Asia
    • In most developing countries, dual energy X-ray absorptiometry (DXA) is expensive and is widely unavailable particularly in the rural areas
  • Calcium intake in almost all Asian countries is below the FAO/WHO recommendations of 1-1.3 g/day
  • Studies done in both sexes and all age groups in different Southeast Asian countries demonstrated widespread incidence of vitamin D deficiency or insufficiency

Risk Factors

Risk Factors in Women for Fracture and Osteoporosis
The more risk factors that are present, the greater the risk of fracture
Non-modifiable
  • Previous history of fracture as an adult
  • History of osteoporotic hip fracture in 1st-degree relative
  • Advanced age [low body weight and older age (Osteoporosis Self-Assessment Tool for Asians - OSTA)]
  • Poor health/frailty
  • Ethnic group (Asians generally have lower risk compared to Caucasians)
  • Early natural or surgical menopause before 45 year of age or prolonged premenopausal amenorrhea >1 year
  • Genetic diseases: Cystic fibrosis, osteogenesis imperfecta, Ehlers-Danlos, hemochromatosis, Marfan syndrome
Modifiable
  • Recurrent falls
  • Decreased body weight [<57.6 kg (<127 lbs)]
  • Impaired vision
  • Medical conditions: Rheumatoid arthritis, estrogen deficiency, Vitamin D deficiency due to lack of sunlight exposure or low intake, thyrotoxicosis, or prolonged Levothyroxine intake
  • Cigarette smoking
  • Excessive alcohol and caffeine intake (≥3 drinks/day)
  • Low calcium (Ca) intake, excessive salt and Vitamin A intake
  • Oral glucocorticoid use ≥5 mg/day of prednisone for ≥3 month
  • Sedentary lifestyle (lack of physical activity)
  • Secondary osteoporosis
  • Lack of sun exposure
Risk Factors in Men for Fracture and Osteoporosis
  • Non-traumatic fractures of the hip, vertebrae or wrist
  • Prior osteoporotic fracture from age 50 years
  • Hypogonadism, growth hormone deficiency
  • Idiopathic hypercalciuria
  • Hyperparathyroidism
  • Rheumatoid arthritis
  • Lymphoma, multiple myeloma
  • Hyperthyroidism
  • Oral glucocorticoid use ≥5 mg/day of Prednisone for ≥3 months
  • Physical inactivity
  • Low body mass index (kg/m2)
  • Anticonvulsants (eg Phenytoin, Phenobarbital)
  • Smoking
  • Alcohol intake (≥3 drinks/day)

Factors Associated with Glucocorticoid-Induced Osteoporosis (GIOP) or Fractures

  • Low bone density
  • Cumulative steroid dose
  • Age >65 years
  • BMI ≤20 kg/m2
  • Smoking, excessive alcohol use
  • Diseases associated with low bone density (eg rheumatoid arthritis, inflammatory bowel disease), sex hormone deficiency, family history of osteoporosis, history of fracture and immobilization
Using FRAX™ score to categorize patient's risk, treatment is recommended for postmenopausal women with:
  • Low risk of fracture (<100%) and intake of  ≥75 mg daily of Prednisolone or its equivalent for >3 months
  • Medium risk of fracture (10-20%) and intake of glucocorticoid at any dose for >3 months
  • High risk of fracture (>20%) and intake of glucocorticoid at any dose for any length of time
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.
Stephen Padilla, 07 Oct 2019
Almost half of Asian patients with dyslipidaemia and hypertension, as well as half of those on pharmacotherapy, have achieved their blood pressure (BP) treatment goals, a Singapore study has shown. Moreover, BP goal attainment is significantly associated with type 2 diabetes mellitus (T2DM) and low-density lipoprotein (LDL-C) control.